Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - lidocaine, quantity: 50 mg/g - gel - excipient ingredients: macrogol 300; macrogol 4000; saccharin; cetrimide; flavour - topical anaesthetic for the oral mucosa for use in children and adults to assist during dental procedures. desensitises the mucous membranes prior to injections. surface anaesthesia for the extirpation of deciduous teeth. abscess incisions below the mucous membrane. extraction of teeth with advanced periodontitis, allows adjustment and fitting of crowns and bridges. allows juxtagingival scaling.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - cetrimide, quantity: 1.5 mg/g; lidocaine, quantity: 50 mg/g - gel - excipient ingredients: spearmint oil; saccharin; macrogol 300; macrogol 4000; macrogol 1500 - topical anaesthesia and disinfection of the mucosa before;,- injections,- extraction of mobile, deciduous or permanent teeth,- extraction of teeth due to pyorrhoea,- adjusting and fitting of crowns & bridges,- lancing of abscesses,- scaling,prevention of gagging during impression taking.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - lidocaine, quantity: 50 mg/g - gel - excipient ingredients: macrogol 4000; macrogol 300; saccharin; cetrimide; flavour - topical anaesthetic for the oral mucosa for use in children and adults to assist during dental procedures. desensitises the mucous membranes prior to injections. surface anaesthesia for the extirpation of deciduous teeth. abscess incisions below the mucous membrane. extraction of teeth with advanced periodontitis, allows adjustment and fitting of crowns and bridges. allows juxtagingival scaling.

Canada - engleză - Health Canada

septodont inc - bupivacaine hydrochloride; epinephrine bitartrate - solution - 5mg; 0.0091mg - bupivacaine hydrochloride 5mg; epinephrine bitartrate 0.0091mg - local anesthetics

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

septodont inc. - articaine hydrochloride (unii: qs9014q792) (articaine - unii:d3sq406g9x), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - articaine hydrochloride 40 mg in 1 ml - septocaine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age or older. septocaine is contraindicated in patients who are hypersensitive to products containing sulfites. products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people [see warnings and precautions (5.5)]. teratogenic effects - pregnancy category c. there are no adequate and well-controlled studies in pregnant women with septocaine. articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (mrhd). septocaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the mrhd based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. in contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the mrhd based on body surface area). in pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the mrhd based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. this dose also produced severe maternal toxicity in some animals. a dose of 40 mg/kg (approximately equal to the mrhd on a mg/m2 basis) did not produce these effects. a similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. it is not known whether septocaine is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when septocaine is administered to a nursing woman. when using septocaine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of septocaine (to minimize infant ingestion) and then resume breastfeeding. safety and effectiveness of septocaine in pediatric patients below the age of 4 years have not been established. safety of doses greater than 7 mg/kg (0.175 ml/kg) in pediatric patients has not been established. the safety and effectiveness of septocaine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections. fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 to 5.1 ml) for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 to 3.9 ml) for complex dental procedures. approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see dosage and administration (2.2)]. in clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received septocaine containing epinephrine 1:100,000. among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 ml) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 ml) were administered to 19 patients for complex procedures. among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 to 11.9 ml) were administered to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 to 5.1 ml) were administered to 4 patients for complex procedures. approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:100,000 injection in patients with renal or hepatic impairment [see warnings and precautions (5.2)].

Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - lidocaine, quantity: 150 mg/g; cetrimide, quantity: 1.5 mg/g - spray, solution - excipient ingredients: saccharin; spearmint oil; dipropylene glycol; ethanol - indications as at 1 january 1991: topical anaesthesia of the mucous membrane of the buccal cavity, before: nerve block or local anaesthetic injection, extraction of mobile, deciduous or permanent teeth, adjustment and fitting of crowns and bridges, or adjustmentof bands in orthodontic treatments; lancing of sub mucosal abscesses, scaling.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

septodont, inc. - mepivacaine hydrochloride (unii: 4vfx2l7em5) (mepivacaine - unii:b6e06qe59j) - mepivacaine hydrochloride 30 mg in 1 ml - mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients. scandonest is contraindicated in patients with a known hypersensitivity to amide-type local anesthetics.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml; adrenaline (epinephrine), quantity: 12.5 microgram/ml (equivalent: adrenaline (epinephrine) acid tartrate, qty 22.8 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; potassium metabisulfite; disodium edetate; sodium hydroxide; water for injections - lignocaine solutions are indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block techniques. lignocaine solutions with adrenaline are recommended for oral surgery requiring prolonged duration of anaesthesia and haemostasis.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

septodont - mepivacaine hydrochloride epinephrine - solution for injection - 2% w/v /1: mg/ml

Australia - engleză - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - mepivacaine hydrochloride; adrenaline -